On November 16, Summit Therapeutics PLC fell 31.55% in Pre-Market Trading, trading at $10.6 per share, with turnover of $518,200.
The move followed disclosure that the FDA issued a complete response letter for the biologics license application for ivonescimab in previously treated advanced lung cancer, meaning the current filing was not approved.
According to the company update, the FDA said the application lacked statistically significant overall survival improvement data. While the Phase 3 HARMONi study showed progression-free survival improvement and an acceptable safety profile, the regulatory setback directly hit sentiment. Recent company disclosures had already highlighted a net loss of $208.4 million in the third quarter, R&D expense of $169.1 million, cash and investments of $629.8 million at the end of September, and shareholder approval to raise authorized common shares to 2 billion, reinforcing investor sensitivity to funding needs and potential dilution.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments